J Med Internet Res:可穿戴设备改善卒中幸存者下肢活动,真的有效吗?

2016-10-23 phylis 译 MedSci原创

背景:随着技术的进步,可穿戴设备已成为脑卒中康复辅助设备。越来越多的卒中幸存者最希望能够恢复步行。尽管研究发现这些设备能够增加下肢的康复,但对其有效性了解甚少。目的:这篇综述主要评估成年卒中幸存者应用可穿戴式技术改善下肢活动有效性方法: 纳入包括应用下肢可穿戴技术进行脑卒中后康复的随机对照试验(RCT)。主要预后措施是按照功能,残疾和健康的国际分类定义活动能力。搜索MEDLINE,科学网(核心),

背景:随着技术的进步,可穿戴设备已成为脑卒中康复辅助设备。越来越多的卒中幸存者最希望能够恢复步行。尽管研究发现这些设备能够增加下肢的康复,但对其有效性了解甚少。

目的:这篇综述主要评估成年卒中幸存者应用可穿戴式技术改善下肢活动有效性

方法:纳入包括应用下肢可穿戴技术进行脑卒中后康复的随机对照试验(RCT)。主要预后措施是按照功能,残疾和健康的国际分类定义活动能力。搜索MEDLINE,科学网(核心),CINAHL和Cochrane图书馆数据库。应用Cochrane风险偏倚工具评估RCT的方法学质量。

结果:在综述中,研究共纳入11项RCT试验,基线时卒中后受试者及对照组共550名参与者,最后一次随访时有474例受试者。参与者的卒中类型和严重程度不同。只有一个研究发现两组间系统功能和活动存在显著差异。在纳入的随机对照试验中,受试者最少为12,最高为151,平均49。在最少受试者的两个研究中,没有人退出RCT,在一个研究中试验中退出19例受试者。11项研究中,有3项研究显示两组间存在显著差异。仅从活动和参与措施来看,P值从P =0.87 到P ≤0.001。

结论:本文强调这些研究的结果需要谨慎对待的原因:样本量低,进行干预的RCT的方法不恰当,缺乏合适的分析结果数据的工具,受试者脑卒中严重程度不同。

原始出处:

Powell L, Parker J, et al. The Effectiveness of Lower-Limb Wearable Technology for Improving Activity and Participation in Adult Stroke Survivors: A Systematic Review. J Med Internet Res. 2016 Oct 7.


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1700685, encodeId=4efd1e006856c, content=<a href='/topic/show?id=82bc38512a4' target=_blank style='color:#2F92EE;'>#可穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38512, encryptionId=82bc38512a4, topicName=可穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db8830213477, createdName=shalley76, createdTime=Tue Apr 11 18:19:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733801, encodeId=ac7e1e33801f4, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Jul 16 11:19:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953938, encodeId=15d01953938a4, content=<a href='/topic/show?id=88ece544685' target=_blank style='color:#2F92EE;'>#穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75446, encryptionId=88ece544685, topicName=穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sat Aug 19 00:19:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018365, encodeId=f560201836531, content=<a href='/topic/show?id=5cac36039a1' target=_blank style='color:#2F92EE;'>#卒中幸存者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36039, encryptionId=5cac36039a1, topicName=卒中幸存者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Thu Dec 08 16:19:00 CST 2016, time=2016-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607168, encodeId=0fdc160e1688f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Oct 25 13:19:00 CST 2016, time=2016-10-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1700685, encodeId=4efd1e006856c, content=<a href='/topic/show?id=82bc38512a4' target=_blank style='color:#2F92EE;'>#可穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38512, encryptionId=82bc38512a4, topicName=可穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db8830213477, createdName=shalley76, createdTime=Tue Apr 11 18:19:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733801, encodeId=ac7e1e33801f4, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Jul 16 11:19:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953938, encodeId=15d01953938a4, content=<a href='/topic/show?id=88ece544685' target=_blank style='color:#2F92EE;'>#穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75446, encryptionId=88ece544685, topicName=穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sat Aug 19 00:19:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018365, encodeId=f560201836531, content=<a href='/topic/show?id=5cac36039a1' target=_blank style='color:#2F92EE;'>#卒中幸存者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36039, encryptionId=5cac36039a1, topicName=卒中幸存者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Thu Dec 08 16:19:00 CST 2016, time=2016-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607168, encodeId=0fdc160e1688f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Oct 25 13:19:00 CST 2016, time=2016-10-25, status=1, ipAttribution=)]
    2017-07-16 canlab
  3. [GetPortalCommentsPageByObjectIdResponse(id=1700685, encodeId=4efd1e006856c, content=<a href='/topic/show?id=82bc38512a4' target=_blank style='color:#2F92EE;'>#可穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38512, encryptionId=82bc38512a4, topicName=可穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db8830213477, createdName=shalley76, createdTime=Tue Apr 11 18:19:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733801, encodeId=ac7e1e33801f4, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Jul 16 11:19:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953938, encodeId=15d01953938a4, content=<a href='/topic/show?id=88ece544685' target=_blank style='color:#2F92EE;'>#穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75446, encryptionId=88ece544685, topicName=穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sat Aug 19 00:19:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018365, encodeId=f560201836531, content=<a href='/topic/show?id=5cac36039a1' target=_blank style='color:#2F92EE;'>#卒中幸存者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36039, encryptionId=5cac36039a1, topicName=卒中幸存者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Thu Dec 08 16:19:00 CST 2016, time=2016-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607168, encodeId=0fdc160e1688f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Oct 25 13:19:00 CST 2016, time=2016-10-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1700685, encodeId=4efd1e006856c, content=<a href='/topic/show?id=82bc38512a4' target=_blank style='color:#2F92EE;'>#可穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38512, encryptionId=82bc38512a4, topicName=可穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db8830213477, createdName=shalley76, createdTime=Tue Apr 11 18:19:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733801, encodeId=ac7e1e33801f4, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Jul 16 11:19:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953938, encodeId=15d01953938a4, content=<a href='/topic/show?id=88ece544685' target=_blank style='color:#2F92EE;'>#穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75446, encryptionId=88ece544685, topicName=穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sat Aug 19 00:19:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018365, encodeId=f560201836531, content=<a href='/topic/show?id=5cac36039a1' target=_blank style='color:#2F92EE;'>#卒中幸存者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36039, encryptionId=5cac36039a1, topicName=卒中幸存者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Thu Dec 08 16:19:00 CST 2016, time=2016-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607168, encodeId=0fdc160e1688f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Oct 25 13:19:00 CST 2016, time=2016-10-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1700685, encodeId=4efd1e006856c, content=<a href='/topic/show?id=82bc38512a4' target=_blank style='color:#2F92EE;'>#可穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38512, encryptionId=82bc38512a4, topicName=可穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db8830213477, createdName=shalley76, createdTime=Tue Apr 11 18:19:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733801, encodeId=ac7e1e33801f4, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Jul 16 11:19:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953938, encodeId=15d01953938a4, content=<a href='/topic/show?id=88ece544685' target=_blank style='color:#2F92EE;'>#穿戴设备#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75446, encryptionId=88ece544685, topicName=穿戴设备)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sat Aug 19 00:19:00 CST 2017, time=2017-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018365, encodeId=f560201836531, content=<a href='/topic/show?id=5cac36039a1' target=_blank style='color:#2F92EE;'>#卒中幸存者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36039, encryptionId=5cac36039a1, topicName=卒中幸存者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6393434, createdName=ailian1202, createdTime=Thu Dec 08 16:19:00 CST 2016, time=2016-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607168, encodeId=0fdc160e1688f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Oct 25 13:19:00 CST 2016, time=2016-10-25, status=1, ipAttribution=)]

相关资讯

青年卒中的7大常见原因

缺血性脑卒中,普遍认为是老龄化的疾病,但近年来,青年缺血性脑卒中的发病率呈逐渐升高的趋势。据世界卫生组织最近统计调查(WHO)显示,青年脑卒中的发病率为(48~240)/ 10 万。国内报道的青年脑卒中占所有卒中的 13.44%。青年患者缺血性脑卒中的病因复杂,危险因素多样化,甚至远多于老年人,常见的和可能原因主要有:一、早发性动脉粥样硬化动脉粥样硬化作为缺血性脑卒中的主要病因之一,在青年人和老年

2015NICE技术评估指南——依度沙班预防非瓣膜性房颤患者卒中和全身性栓塞(TA355)发布

2015年9月,英国国家卫生与临床优化研究所 (NICE)发布了依度沙班预防非瓣膜性房颤患者卒中和全身性栓塞的技术评估指南。全文获取:下载地址:指南下载(需要扣积分2分, 梅斯医学APP免积分下载) 

Circulation:短时间发作房性心动过速/房颤,会不会增加不良事件风险?

RATE(房性心动过速和房颤)注册表是一项前瞻性、结果导向的注册表,旨在记录植入心脏起搏器、心律转复除颤器(ICDs)患者的房性心动过速和/或房颤(AT/AF)的发生情况,以及AT/AF和预定义的临床事件(包括卒中)之间的联系。 长期AT/AF定义为电描记图(EGM)上记录到的发病和消退并不是在一个单一的(EGM)记录上。短期AT/AF则指AT/AF发作和消退情况记录在单次EGM上。

如何鉴别卒中与心脏病发作?

导语:心脏病发作与卒中均是可危及生命的紧急医疗事件,两者既有相似之处,又有不同之处。只有充分了解两者的症状及体征,才能实现快速准确的诊断及治疗,从而提高其生存率及全面恢复的可能性。一、常见症状——当流至冠状动脉的血液减少或被阻断时会影响心脏供血从而导致心脏病发作,美国每 43 秒就有一例心脏病发作。心脏病发作的常见症状包括胸部疼痛及不适、上身不适、气短、突发冷汗、疲劳、恶心、头晕或眩晕;但不同患者

AM J MED:外源性睾酮治疗会增加心血管风险吗?

外源性睾酮治疗与其他治疗或安慰剂相比,是否会增加男性的严重心血管事件风险? 本项系统回顾和荟萃分析,纳入了相关随机对照试验(RCT)和观察性研究,参与者为18岁或以上男性,接受外源性睾酮治疗3天或以上。 主要结果是全因死亡、心肌梗死和卒中。次要终点是其他临床结果,如心脏衰竭、心律失常和心脏手术。 共纳入39项随机对照试验和10项观察性研究。使用30项随机对照试验的数据合并后进行荟

J Am Soc Nephrol:HDL胆固醇的流出能力不能预测血透患者心血管发生的风险

高密度脂蛋白(HDL)的保护作用主要是由胆固醇流出能力决定的,这表明肾功能正常人群中HDL与动脉粥样硬化性心血管疾病是负相关的。终末期肾病患者ESRD有异常高的心血管风险,这些风险不能完全由传统的危险因素解释。在这里,对参与德国糖尿病透析研究中的1147例血液透析的2型糖尿病患者进行post-hoc分析,研究者调查高密度脂蛋白胆固醇流出能力是否能预测心血管风险。通过孵化人巨噬细胞消耗血清apoB量